Stockholm August 25, 2021 - Intervacc has stated in the published financial calendar that the report for the first half of 2021 would be made public on September 3, 2021. The report will be made public on August 31, ... Read more
Stockholm, August 23, 2021 - Intervacc AB (“Intervacc”) announced today that the Norwegian Medicines Agency (NoMA) has granted a marketing authorisation for Strangvac® within Norway. Strangvac® is ... Read more
Stockholm, August 16, 2021 - Intervacc AB (“Intervacc”) announced today that the European Commission has granted a Marketing Authorisation for Strangvac® within the European Union. Strangvac® is a vaccine against equine ... Read more
Stockholm, July 2, 2021 - Intervacc AB (“Intervacc”) announced today that the Veterinary Medicines Directorate (VMD) of the United Kingdom has give a positive outcome on their application for a Marketing Authorisation ... Read more
